Risk stratification of pediatric AML is mostly based on cytogenetics; however, some recurrent mutations such as NPM1, CEBPA, and FLT3-ITD with WT1 are also included in most risk classifications.41 The gene discussed is CEBPA; the disease is acute myeloid leukemia.